CD4 and neoplasm: AdVTMM2, an E1/E3-deleted adenovirus encoding three full length melanoma antigens (tyrosinase, MART-1 and MAGE-A6), expresses mRNA and protein for all antigens, and AdVTMM-transduced DCs activate both CD8+ and CD4+ T cells that recognise melanoma tumour cells more efficiently than single antigen adenovirus-DC vaccines [51].